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1.0 INTRODUCTION 
Fixed Dose Combination (FDCs) is the widely used 
approach due to its improved medical compliance of 
patients. A fixed dose combination (FDCs) is a 
formulation of two or more active ingredients combined in 
a single dosage form available in certain fixed doses. 
Recently in India, Fixed Dose Combination (FDCs) of 
drugs/medicines has drawn the attention of health service 
providers and the service recipients.1 FDCs are the current 
hot topic of deliberations in the pharmaceutical industry, 
government (as regulators), NGOs and the pharmaceutical 
trade. Surprisingly, it is not so among the doctors who 
prescribe the medicines or the patients who consume. 
Technically, on one hand it increases patient compliance, 
but on the other hand there are chances of consuming 
medicines (FDCs available in market in India), more than 
what is required.1, 2  
Advantages of Fixed Dose Combinations
2 
 Simpler dosage schedule improves compliance and 
therefore improves treatment outcomes 
 Prevents and/or slows attainment of antimicrobial 
resistance by eliminating monotherapy (i.e, one drug 
is never by itself in circulation) 
 Allows for synergistic combinations (i.e., 
trimethoprim/ sulfamethoxazole combination allows 
each drug to se lectively interfere with successive 
steps in bacterial folate metabolisms 
 Eliminates drug shortages by simplifying drug storage 
and handling, and thus lowers risk of  being “out of 
stock” 
 Only 1 expiry date simplifies dosing (single products 
may have different expiry dates). 
 Potential for drug abuse can be minimized by using 
one drug of the combination for this purpose (i.e., 
excessive use of the antidiarrheal narcotic 
diphenoxylateis discouraged by side effects of 
atropine in the FDC atropine + diphenoxylate) 
 Side effects are reduced by using one drug of the 
combination for this purpose 
Disadvantages of Fixed Dose Combinations
2 
 FDCs are (possibly) more expensive than separate 
formulations. 
 Potential quality problems, especially with Rifampicin 
in FDCs for TB, requiring bio-availability testing 
 If a patient is allergic or has a side-effect to 1 
component, the FDC must be stopped and replaced by 
separate tablets 
 Dosing is inflexible and cannot be regulated to 
patient‟s needs (each patient has unique characteristics 
such as weight, age, pharmacogenetics, co-morbidity, 
that may alter drug metabolism and effect). 
 Drug interactions may lead to alteration of the 
therapeutic effect. 
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Fixed Dose Combination in Migraine Therapy 
According to investigation of S. Evers et. Al., migraine is 
one of the most frequent disabling neurological conditions, 
which also impact the quality of life.3, 4 According to 
migraine research foundation about 18 percent of women 
and 6 percent of men suffer from migraines. Migraine is 
also a major concern in pediatrics. About 10 percent of 
school-age kids get migraines; In fact, about 50 percent of 
the people who get migraines first experience them before 
they‟re 12.5  
There are server fixed dose combination are available in 
the treatment of migraine. Caffeine and metoclopramide 
are used in combination with analgesics and ergotamine in 
the treatment of migraine attacks.6 As per the report of S. 
Evers et. Al. (2006), fixed combination of Acetyl salicylic 
acid, Paracetamol, and caffeine is effective in acute 
migraine treatment and is also more effective than the 
single substances or combinations without caffeine.7, 8 
Sumatriptan with combination of Naproxen is also 
effective in fixed dose combination for migraine.9  
Rationale behind Selection of Tolfenamic Acid & 
Paracetamol as FDCs  
Tolfenamic acid (TA) is one of the classes of non-steroidal 
anti-inflammatory drugs (NSAIDs). It is used to treat the 
symptoms of migraine. A study concludes, "Tolfenamic 
Acid was found significantly better than placebo in the 
subjective evaluation of drug efficacy (p<0.001) and in 
reducing the reported hangover symptoms in general (p < 
0.01). In the Tolfenamic acid group, significantly lower 
symptom scores were obtained for headache (p<0.01), and 
for nausea, vomiting, irritation, tremor, thirst and dryness 
of mouth (all p < 0.05).10  Paracetamol (4'-
hydroxyacetanilide, N-acetyl p- aminophenol, 
acetaminophen, PAR) is a widely used over-the-counter 
analgesic and antipyretic drug without any gastric irritation 
and ulcerative effects. 8, 11 Existing fixed dose combination 
of Acetyl salicylic acid and caffeine is not recommended 
for pediatrics due to side effect of opoids in caffeine.4 The 
combination of Paracetamol with Tolfenamic acid is the 
next choice of drug due to lower side effects both the 
actives. On the basis of literature and market survey it was 
observed that still it is rare to find any suitable fixed dose 
combination of rapid dispersible formulations in migraine 
therapy for pediatrics, so there is need to develop a 
formulation with effective taste masking.12, 13 So the 
present study was designed with aim to formulate an 
effective fixed dose combination with rapid release profile 
to make more Pharmaco -dynamically active formulation. 
2.0 MATERIALS AND EQUIPMENTS 
Tolfenamic Acid, Paracetamol, Aspartame and Flavor 
Vanilla was a gift sample from Elder Pharmaceuticals Ltd, 
Navi Mumbai, India. Microcrystalline cellulose, Sodium 
Lauryl sulfate, Povidone, Mannitol, Eudragit-EPO, 
Polyethylene Glycol, Methanol, Hypromellose, Talc, 
Magnesium Stearate, Crospovidone and Ac-di-sol were 
obtained from commercial sources. 
3.0 MANUFACTURING OF GRANULES AND 
TABLETS
14, 15, 16 
The basic aim of the study was to formulate a fixed dose 
formulation of Tolfenamic Acid and Paracetamol. Two 
separate granulation with different approaches were 
applied for manufacturing of Tolfenamic acid and 
Paracetamol granules. Manufacturing of Tolfenamic acid 
was prepared by using co-micronization technique.14 The 
manufacturing of Paracetamol granules was prepared by 
using solid dispersion and wet granulation method.15, 16 
The basic aim behind using the novel technologies in 
development of fixed dose combination of Tolfenamic acid 
and Paracetamol were to improve the release profile of 
active for rapid action of formulation. The details of 
formulations were summarized in the Table 1.0.   
3.1 Manufacturing of Granules 
3.1.1 Manufacturing of Tolfenamic Acid Granules
17 
A – Solubility Enhancement of Tolfenamic Acid  
Solubility enhancement of Tolfenamic acid was done by 
using co-micronization technology. Co-micronization of 
TA with MCC was done by using Air-jet mill, total three 
cycle of micronization was completed to insure the proper 
particle size reduction of blend. Milling of blend was 
performed at primary pressure 4.5-5.0 kg/cm2, secondary 
pressure 4.0-4.5 kg/cm2, and screw feeder speed 6-7 rpm.  
B – Granulation of Tolfenamic Acid  
Co-micronized blend of Tolfenamic acid was mixed in 
rapid mixer granulator (HSMG-10, Kevin Machinery) with 
slow impeller speed (75 RPM) for 10 minutes, PVP K-30 
was dissolved in distilled water to give a binder 
concentration of 6.0 % w/v. To granulate, the binder was 
added slowly over five minutes through a glass funnel to 
control the flow rate. The resultant material was wet 
massed through the required sieve. Granules were vacuum 
dried using vacuum dryer (Shree Engineering) at 55°C for 
150 – 180 minutes. In addition to the temperature and the 
duration of the drying process, the moisture content and 
flow rate of the circulating air could affect granule strength 
and therefore to standardize, the amount of granules in 
each tray-dried was kept within an approximate range of 
600-900g. The residual granule moisture content was 
determined by loss on drying. Granules were stored in 
double polythene bags until use to prevent moisture loss / 
gain. The dried granules than blended with extra granular 
excipients as per the given details of formulation in table 
1.0 using  bin blender (Solace Engineering) at 12 RPM for 
10 minutes. The blends were lubricated with Magnesium 
Stearate using bin blender at 12 RPM for 3 minutes.   
3.1.2 Manufacturing of Paracetamol Granules
17, 18 
A – Solubility Enhancement of Paracetamol 
Solubility enhancement of Paracetamol was done by using 
solvent dispersion method. Solid dispersion of Paracetamol 
was prepared with dissolving Paracetamol with weighed 
quantity of Methanol, the solution was stirred for 3 hrs to 
make transparent solution of dispersion phase, the 
prepared solution than slowly dispersed on the solid 
material with continuous triturating to ensure proper 
mixing of dispersion solution, finally the mixture is 
allowed to dry at 600C for 8 hrs in Vacuum tray drier 
(Shree Engineering). The dried solid dispersion of 
Paracetamol was passed through #60 mesh to ensure the 
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uniform particle size for further processing at next stage 
such as formulation of Paracetamol granules.    
B – Granulation of Paracetamol (SD) Granules 18 
Wet granulation method was adopted to manufacture 
Paracetamol (SD) granules. Granulation is required to 
make proper flow during compression stage. Solid 
dispersion blend of Paracetamol was granulated by using 
rapid mixer granulator (HSMG-10, Kevin Machinery). 
Binder solution was prepared by dissolving the 
hypromellose in Luke warm purified water. The 
concentrations of binder used were kept at 6 % w/w to 
make uniform granule. The wet mass was granulated by 
passing them manually through a number 12 mesh sieve. 
Granules were dried at 60oc in vacuum tray dryer (Shree 
Engineering) again sizing through number 20 mesh sieve 
(Yayoi Kawano et al, 2010).18 
 
Table 1: Formulation details of Tolfenamic Acid and Paracetamol Tablets 
Ingredients/   
Formulation Code 
Quantity in each tablets (mg/tabs) 
A-1 A-2 A-3 A-4 
Part – 1 Tolfenamic Acid Granules 
Tolfenamic Acid 100.00 100.00 100.00 100.00 
Microcrystalline Cellulose 50.00 50.00 50.00 50.00 
Sodium Lauryl Sulfate 1.25 1.25 1.25 1.25 
Povidone (PVP K-30)  2.50 2.50 2.50 2.50 
Purified Water QS QS QS QS 
Part – II Paracetamol Granules 
Paracetamol 125.00 125.00 125.00 125.00 
Mannitol 125.00 125.00 125.00 125.00 
Hypromellose 5.00 5.00 5.00 5.00 
Eudragit – EPO 25.00 25.00 25.00 25.00 
Polyethylene Glycol 5.00 5.00 5.00 5.00 
Talc 5.00 5.00 5.00 5.00 
Purified Water QS QS QS QS 
Lubrication of Granules 
Ac-di-sol 25.00 -- 25.00 -- 
Crospovidone -- 25.00 -- 25.00 
Aspartame 5.00 5.00 5.00 5.00 
Flavor Vanilla 5.00 -- -- 5.00 
Flavor Strawberry -- 5.00 5.00 -- 
Magnesium Stearate 1.25 1.25 1.25 1.25 
Tablet Weight in mg 480.00 480.00 480.00 480.00 
 
C – Taste Masking of Paracetamol (SD) Granules17 
The dried granules than loaded in fluid bed processor (Pam 
Glatt), the taste masking polymer solution was prepared by 
adding Eudragit-EPO in purified water with continuous 
stirring, than Poly ethylene glycol , and talc was added in 
the coating solution to make dispersion of coating 
suspension (Dinkar Sharma et al, 2012). The loaded 
granules were coated in fluid bed processor using top spray 
granulation. The initial spray rate and air flow was kept 
slow to avoid any fines generation during polymer coating. 
The coated granules were additionally dried for 30 minutes 
at 600C for proper curing of taste masking granules of 
Paracetamol. The coated granules of Paracetamol was 
passed through #20 meshes and were mixed with 
disintegrants and than lubricated with Magnesium Stearate 
in Lab model Bin Blender (Solace Engineering).  
3.1.3 Lubrication of Granules 
Lubrication of Tolfenamic acid and Paracetamol granules 
were done by mixing of Tolfenamic acid and Paracetamol 
granules in a suitable blender.  
3.2 Manufacturing of Tablet
17 
The compression of granules was completed by using 
Cadmach single rotary compression machine. Chrome 
plated punching tools was used to avoid any sticking 
problem during compression. The average turret speed 
during compression was also kept in range of 10 – 12 
RPM. In preliminary work, problems with uncontrolled 
moisture sorption occurred in granules during tabletting. 
The relative humidity of the tabletting area monitored 
during compression of tablets. Limit of 50% RH was set as 
the maximum relative humidity at which tabletting was 
carried out. 
4.0 PHYSICAL EVALUATION OF GRANULES 
4.1 Physical evaluation of Co-micronization blend
19 
The evaluation of micronized mixtures of Formulation A-1 
to A-4 was confirmed for particle size of TA mixture. The 
particle size was evaluated by using Malvern Mastersizer 
2000. The average particle size which was the mean 
particle size of 90% (d-0.9) of particle in sample was 
recorded for evaluation.19  
4.2 Loss on drying
20 
Loss on drying is the loss of weight expressed as 
percentage w/w resulting from water and volatile matter of 
any kind that could be driven off under specified 
conditions. The loss on drying was calculated by using 
equation,  
% 𝐿𝑂𝐷 =
Weight of solvent in sample
Total weight of initial sample
X100 
Anand et al                                Journal of Drug Delivery & Therapeutics; 2013, 3(2), 114-124   117 
© 2011, JDDT. All Rights Reserved                                                        ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 Approximately 2.0 gms of dried granules were placed on 
aluminum disk of IR moisture balance. The loss on drying 
was recorded at 1050C for 10 minutes of time interval .20  
4.3 Tapped and Untapped Density
20, 21 
Un-tapped and tapped density was determined by placing a 
graduated cylinder containing a known mass of drug on a 
mechanical tapper apparatus which was operated for fixed 
number of taps (~ 100) until a powder bed volume had 
reached the minimum. The ratio of mass (weight) to 
volume is known as the untapped bulk density of material . 
The bulk density of a powder depends on particle size 
distribution. The equation for determining the bulk density 
and tapped density is, 
ρb =
M
Vp
 
ρt =
M
Vt
 
Where, „ρb‟ is untapped bulk density, „ρt‟  is tapped 
density , „M‟ is weight of sample in grams, „Vp‟ i s  final 
volumes of powder in cm3, „Vt‟ is tapped volume of 
powder in cm3. 
4.4 Compressibility Index
20, 21 
The compressibility index of the granules was determined 
by Carr‟s index. The Carr‟s index was determined from the 
tapped density and poured density (bulk density) as per the 
formula given below, 
𝐶𝑎𝑟𝑟 ′𝑠 𝐼𝑛𝑑𝑒𝑥  % 
=
Tapped Densit − Bulk Density
Tapped Density
X100 
 
4.5 Hausner Ratio
20, 21 
Hausner Ratio was determined from the ratio of tapped 
density to bulk density using formula given below.  
𝐻𝑎𝑢𝑠𝑛𝑒𝑟 𝑅𝑎𝑡𝑖𝑜 =
Tapped Density
Bulk Density
 
Flow of granules was evaluated by using interpretation 
between Hausner Ratio and carr‟s index as shown in Table 
– 2.0. 
Table 2: Interpretation by Hausner Ratio 
Hausner’s Ratio Interpretation Equivalent Carr’s Index 
1.25 Good flow 20% 
>1.25 Poor flow 33% 
 
4.6 Angle of Repose
20, 21 
Angle of repose of samples were measured by employing 
fixed height method, the specific amount of sample was 
poured through the funnel from the height of 2cm anker 
GS et. Al 1987). The diameter of pile formed was 
measured and angle of repose was calculated by using 
following formula, 
θ =
h
r
 
Where, „θ‟ is angle of repose, „h‟ is height, and „r‟ is 
radius. The flow properties of granules were than 
interoperated by using table as shown in table 3.0. 
Table 3.0: Interpretation of Angle of Repose 
Flow Properties Angle of Repose 
Excellent 25-30 
Good 31-35 
Fair-aid not needed 36-40 
Passable-may hang up 41-45 
Poor-must agitate, vibrate 46-55 
Very poor 56-65 
 
5.0 PHYSICAL EVALUATION OF TABLETS 
5.1 Appearance 
Appearance of tablets was evaluated by taking twenty 
tablets of each formulation and visually checked for any 
discoloration or surface roughness on the core surface of 
tablet formulation. 
5.2 Weight Variation of tablets
22, 23
 
 
Weight variation of tablets was calculated by weighing 20 
tablets individually and determining the average weight. 
Tablet meets the test if not more than two of the individual 
weights deviate from percentage limits of 7.5% (Indian 
Pharmacopoeia, 2010).    
5.3 Hardness
22, 23
  
The hardness of six tablets was determined using the 
Erweka type hardness tester and the average values were 
calculated for each formulation trials. 
5.4 Thickness
22, 23
  
The Thickness of the tablets was determined by using 
Digital vernier calipers (Mitutoyo, Japan). Six tablets were 
used, and average values were calculated for each 
formulation trials. 
5.5 Friability
22, 23, 24 
It was intended to determine the loss of mass under 
defined conditions. The friability of uncoated tablets was 
determined by using Electro lab Friability Apparatus. The 
20 pre weighed tablets were paced in friability apparatus 
and tested for the effects of abrasion and shock by utilizing 
a plastic chamber that revolves at 25 rpm dropping the 
tablets at a distance of six inches with each operation for 
100 revolutions (Indian Pharmacopoeia, 2010). The tablets 
are then de dusted and reweighed. The percentage for 
friability than calculated using following formula, 
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𝐹𝑟𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦  % 
=
Initial weight of Tablets− Final weight of Tablets
Initial weight of Tablets
X100 
As per the Indian pharmacopoeia the limit for friability 
tablets should not be more than 1% w/w. The  values  for  
both  Hardness  &  Friability  can  together  indicate  the  
mechanical strength of tablet. 24  
5.6 Disintegration Time
22, 23, 18, 25 
Disintegration is defined as time required by tablet to 
completely disintegrate and disappear from the basket. 
Disintegration time of tablets was evaluated as per the 
specification of disintegration time of dispersible and 
Orodispersible tablets in British pharmacopoeia. 
Disintegration was carried out by using 600ml of 
disintegration media mentioning the temperature at 150C – 
250C in disintegration basket.18 Disintegration discs were 
not used during disintegration. The use of discs during 
disintegration reduces discrimination between good and 
bad formulations since the palpable residue on the mesh 
would not pass through without applying pressure and thus 
violating the principle of fluid penetration and particle 
separation.25  
5.7 In vitro dispersion Time and Fineness of 
Dispersion
22, 23, 26 
Fineness of dispersion is specified in the specification of 
dispersible tablets (British Pharmacopoeia 2010). This 
taste is required to check the fineness and smoothness of 
dispersion of tablets. The same concepts were applied to 
correlate the dispersion of tablets in vivo by using pH 6.8 
phosphate buffers. The in vitro dispersion time was 
observed by placing one tablet in a beaker containing 50 
ml of pH 6.8 phosphate buffer at 370C + 10C, the time 
required to disperse the tablets was determined.26 The 
same dispersion was passed through a sieve screen with a 
nominal mesh aperture of 710 mm to confirm the fineness 
of dispersion. 
5.8 Wetting Time and Water Absorption Ratio
18, 24 
Water absorption ratio of tablet was evaluated by using 
aqueous solution of Methylene Blue. It is also an 
indicating method to evaluate the disintegrating 
mechanism of tablets.18 Absorbent cotton soaked with 0.04 
% aqueous solution of methylene blue was placed in a 
Petri dish, the tablets was placed flat on the surface of 
cotton, and the time required to change the color of whole 
tablets to blue was measured as water absorption time. 
Total six tablets were used for the investigation of water 
absorption time and mean of water absorption time was 
calculated .24   
Water absorption ratio (WAR) was calculated by using the 
pre weight and post weight of tablet used for wetting time 
evaluation by using following equation, 
𝑊𝐴𝑅  𝑅 
=
Weight of wetted tablets − Weight of dry Tablets
Weight of dry Tablets
 X 100 
 6.0 ANALYTICAL EVALUATION OF TABLETS23, 27 
6.1 Assay of Drug Content in Tablets
23, 27
  
The analysis for drug content of formulation was 
developed by HPLC method on the basis specification of 
individual active in pharmacopoeia and other 
physicochemical properties.23, 27  
Chromatographic condition 
Mobile Phase : Acetic Acid: Water: Ethanol (2:25:75), filter and degas. 
HPLC Column : C18, 250 mm x 4.6mm, 5 µ or equivalent 
Flow rate : 1.0 ml/min 
Detector : 232 nm for Paracetamol & 285 nm for Tolfenamic acid 
Injection vol : 10 µl 
Run Time : 15 min. 
Retention time : Paracetamol: about 3.0 min. 
Tolfenamic Acid: about 8.0 min. 
Standard Solution 
Preparation 
: Transfer an accurately weighed quantity of about 62.5 mg of Paracetamol WS and 50.0 mg 
of Tolfenamic Acid WS in a 100 ml volumetric flask. Add about 60 ml of mobile phase and 
sonicate for about 10 minutes to dissolve. Dilute up to the mark with mobile phase and mix 
well. Further dilute 5 ml of above solution to 50 ml with mobile phase. Use the filtrate for 
chromatographic injection. 
Sample Preparation : Weigh and finely powder not less than 20 Tablets and transfer an accurately weighed 
quantity of powder equivalent to about 125 mg of Paracetamol & 100 mg of Tolfenamic 
Acid (one tablet) into a 100 ml volumetric flask. Add about 70 ml of mobile phase, and for 
about 20 minutes to dissolve. Dilute up to the mark with mobile sonicate phase and mix 
well. Filter the solution through 0.45 µ, filter discarding the first few ml of the filtrate.  
Further dilute 5 ml of above solution to 100 ml with mobile phase. Use the filtrate for 
chromatographic injection.  
For Paracetamol            Ru  x  Std. Wt   x  5    x   100  x   100   x  P     
                                                                                      x   Avg. Wt.                
           Rs   x   100   x   50  x  Spl. wt  x  5  x   100        
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  Where, 
  Ru and Rs are peak responses of sample and std preparation in mg 
  P is the purity of Paracetamol WS on as is basis. 
Calculate the % labeled amount, since label claim of Paracetamol is 125 mg/tablets. 
For Tolfenamic Acid         Ru  x  Std. Wt   x  5    x   100  x   100   x  P     
                                                                                  x   Avg. Wt.                
       Rs   x   100   x   50  x  Spl. wt  x  5  x   100       
  Where, 
  Ru and Rs are peak responses of sample and std preparation in mg 
  P is the purity of Tolfenamic Acid WS on as is basis. 
Calculate the % labeled amount, since label claim of Tolfenamic Acid is 100 mg/tablets. 
6.2 In-vitro Drug Release Kinetics
 
In-vitro dissolution studies of all formulation were 
evaluated for the release profile of formulation. The basic 
objective of formulation was to develop the rapid 
disintegrating formulations, so release profile at various 
time intervals such as 5, 10, 15, 30, 45, and 60 minutes 
were analyzed for the evaluation of release kinetics. The 
separate dissolution for Tolfenamic acid and Paracetamol 
was performed as per the given method in British 
Pharmacopoeia.  
Dissolution of Tolfenamic Acid 
USP dissolution apparatus      : Type-II Paddle, 100 RPM 
Dissolution Medium      : 1000 ml, Phosphate Buffer pH 7.2  
Temperature              : 37 ± 0.5 0C 
Sampling Times (minutes)  : 5, 10, 15, 30, 45, and 60 
 
Dissolution of Paracetamol  
USP dissolution apparatus         : Type-II Paddle, 50 RPM 
Dissolution Medium: 900 ml, Phosphate Buffer pH 5.8  
Temperature  : 37 ± 0.5 0C 
Sampling Times (minutes) : 5, 10, 15, 30, 45, and 60 
 
Dissolution Procedure  
Dissolution of tablets was initiated by placing one tablet in 
each of six vessels containing respective dissolution 
medium, using paddle apparatus at respective paddle rpm 
for 60 minutes.  
7.0 ORGANOLEPTIC EVALUATION
 18 
The objective of this study is to conduct and evaluate the 
Palatability of different formulations of Tolfenamic Acid 
and Paracetamol Dispersible Tablets. Paracetamol is 
bitterer as compare to Tolfenamic Acid, so the taste 
evaluation also designed to check the bitterness of 
Paracetamol in FDCs. All four formulations were selected 
for taste evaluation study with a team of 10 members for 
taste evaluation. The taste score between 1 and 5 was 
given to evaluate the taste of formulation. Namely, the 
scores were set as follows: 1 (Distasteful, equivalent to 
Paracetamol taste), 2 (Slightly taste, Paracetamol taste 
remaining fairly), 3 (Mean, Paracetamol taste remaining to 
some extent), 4 (slightly tasty, Paracetamol taste slightly 
remaining), 5 (Tasty, no taste of Paracetamol). The mean 
observation was recorded in the evaluation sheet. 
8.0 STABILITY STUDIES
18, 19 
Stability studies are essential to every phase of drug life-
cycle. The objective of the current study was to perform 
the various physical and analytical properties of finished 
product at specified temperature and humidity for a 
definite time interval. It is also required to understand any 
significant physical and analytical changes in the product, 
with time under the influence of variety of environmental 
factors to which drug product may be exposed during its 
shelf life.  
9.0 RESULT AND DISCUSSION 
9.1 Physical Evaluation of Granules 
A – Co-micronization blend of Tolfenamic Acid 
The average particle size which is the mean particle size of 
90% (d-0.90) of particle in sample was recorded for 
evaluation ad tabulated in the Table 4.0 Graph 1.0. The 
average particle size of all formulation A-1 to A-4 showing 
similar particle size profile,  which was reflecting an 
effective and reproducible results of co-micronization 
processing of Tolfenamic acid using Air jet mill. 
 
Table 4: Particle size distribution of Co-micronized blend of Tolfenamic Acid 
Formulation 
Average Particle Size 
(d-0.90) in µm 
Particle Size (d-0.50) in 
µm 
Particle Size (d-0.10) in 
µm 
A-1 12.23 6.23 3.36 
A-2 11.65 7.01 3.08 
A-3 12.80 6.90 2.96 
A-4 10.29 7.36 3.39 
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B – Physical Evaluation of Granules 
The various physical evaluation of lubricated blend such as 
loss on drying, tapped and untapped density, compressive 
index, Hausner ratio, and angle of repose for formulation 
A-1 to A-4 were summarized in table 5.0. 
Since there was not any major difference up to drying step 
in all formulation, so the physical properties of granules 
was found similar to each other. The loss of drying for 
formulation A-4 was 1.96 % w/w , which was on higher 
side as compare to remaining formulation such as A-1, A-
2, and A-3 as 1.63% w/w, 1.73% w/w, 1.49% w/w 
respectively. The variation in moisture may be due to 
uptake of water during granulation stage. There were some 
variation observed in the density profile of lubricated 
blend but it was not having any significant impact on the 
properties of granules.  Compressive index (Carr‟s Index) 
of blend was found as 18.32%, 22.64%, 19.34%, and 
25.33% for formulation A-1, A-2, A-3, and A-4 
respectively. On the basis of compressive index, flow 
properties of blend indicating fair to poor flow of granules, 
the poor flow of granules probably due to higher moisture 
content of formulation A-4. There were various reasons 
other than compressibility index of granules such as 
density profile, angle of repose playing a significant role in 
flow of granules, so the correlation of all the physical 
parameters needs to be considered during compression 
stage. Angle of repose of granules was also evaluated to 
confirm the flow of granules, the values of angle of repose 
was found in the range of 34 – 36 indicating a fair to good 
flow of granules. So on the basis of various physical 
properties of granules; it was clearly indicating the 
justified selection of intra granular diluents such as 
microcrystalline cellulose and mannitol during wet 
granulation stage of individual formulations. 
  
 
Graph 1: Particle size distribution of Co-micronized blend of Tolfenamic Acid 
Table 5: Physical properties of Granules (n=3) 
Physical Properties A-1 A-2 A-3 A-4 
Loss on drying (%w/w) 1.63 ± 0.06 1.73 ± 0.06 1.49 ± 0.08 1.96 ± 0.06 
Bulk density (gm/ml) 0.47 ± 0.03 0.45 ± 0.03 0.50 ± 0.02 0.40 ± 0.16 
Tapped density (gm/ml) 0.58 ± 0.02 0.59 ± 0.03 0.62 ± 0.03 0.54 ± 0.01 
Carr‟s Index (%) 18.32 ± 1.52 22.64± 1.47 19.34 ± 1.14 25.33 ± 1.48 
Hausner‟s Ratio 1.23 ± 0.02 1.34 ± 0.03 1.24 ± 0.02 1.29 ± 0.02 
Angle of Repose 35.53 ± 0.50 36.66 ± 0.58 34.00 ± 1.00 35.53 ± 0.50 
 
9.2 Physical Evaluation of Tablets 
The various physical evaluation for tablets of formulation 
A-1 to A-4 were summarized in table -6.0. 
The appearance of tablets found good without any 
significant defects. Weight variation data for all the 
formulations batches indicated no significant difference in 
the weight of individuals tablets from the average value 
and weight variation were found to be within limits. The 
value of hardness friability of tablet showed good strengths 
in all formulation, which is an essential parameter for 
formulation of Dispersible tablets. The thickness of tablets 
was also within limit. On the basis of comparative 
evaluation of hardness of tablets with friability, friability 
of tablets was increasing with reducing the hardness of 
tablets.   
Table 6: Physical Evaluation of Tolfenamic Acid and Paracetamol Tablets 
Evaluation Parameters A-1 A-2 A-3 A-4 
Appearance Off-white colored, Caplet shape tablet 
Weight Variation (%) 482.36± 2.35 480.96± 1.93 479.36± 2.46 478.39± 2.29 
Hardness (Newton) n=6 39.59± 2.50 35.26± 2.10 40.03± 2.16 30.00± 1.26 
Thickness (mm) n=6 3.22± 0.04 3.20± 0.06 3.19± 0.04 3.21± 0.05 
Friability (% w/w) 0.65 0.76 0.60 0.82 
Disintegration (Seconds) 80 – 90 60 – 70 85 – 95 50– 60 
Dispersion (Seconds) n=3 115.00± 5.00 74.33± 4.00 105.00± 5.00 62.33± 2.50 
Wetting Time (Seconds) n=3 125.00± 5.00 79.00± 3.61 111.67± 2.89 62.67± 6.81 
Water Absorption Ratio 43.57 47.49 43.89 47.61 
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The average disintegration time for formulation A-1, A-2, 
A-3, and A-4 was 85, 65, 90, and 55 second respectively. 
The changes in disintegration time reflecting the impact of 
disintegrants during compression stage. There was some 
significant difference observed in dispersion and  wetting 
time of formulation, the dispersion time and wetting time 
was higher for formulation A-1 and A-3 as compare to 
formulation A-2 and A-4. The rapid dispersion and wetting 
reflects the effect of super disintegrants in lubrication stage 
of granulation. Use of Crospovidone showing rapid 
bursting and wetting effect as compare to Ac di sol during 
compression stage. Higher wetting tendency of tablets 
during dispersion of tablets may also due to usage of 
sodium lauryl sulfate during granulation stage. 
Micronization of Tolfenamic acid during granulation stage 
also one of the reason behind rapid dispersion of tablets. 
Same phenomenon of rapid dispersion and wetting reflects 
in water absorption ratio.  The water absorption ratio for 
formulation A-2 and A-4 was found higher as comparison 
to remaining formulation.  So there is clear impact of 
disintegrants in enhancement of physical properties of 
formulations. The comparative evaluation of 
disintegration, dispersion and wetting time between 
different formulations were also shown in Graph 2.0. 
Since the present study was focused on the combination of 
two actives such as Tolfenamic Acid and Paracetamol in 
formulation of FDCs, the rapid dispersible granules were 
utilized in formulation of dispersible tablets. There were 
no significant changes observed due to combination of 
Tolfenamic acid and paracetamol in fixed dose 
combination. The basic requirement of rapid disintegration 
and dispersion with acceptable hardness also achieved in 
formulation of the FDCs of Tolfenamic acid and 
Paracetamol tablets.  The diagrammatic presentation of 
dispersion tendency of tablets is shown in Figure – 1.0.
   
 
Graph 2: The comparative evaluation of disintegration, dispersion and wetting time between different formulations 
 
Figure 1: Dispersion of Tolfenamic Acid and Paracetamol Tablets 
 
9.3 Analytical Evaluation of Tablets 
The assay of drug content and in vitro drug release profile for tablets of formulation A-1 to A-4 were summarized in Table 
– 7.0 and Graph 3.0 and 4.0. 
Table 7: Assay of Drug Content in Tablets 
Evaluation Parameters A-1 A-2 A-3 A-4 
Drug Content (%) n=3 
(Tolfenamic Acid) 
98.65± 1.30 100.69± 1.97 102.25± 1.30 100.05± 1.24 
Drug Content (%) n=3 
(Paracetamol) 
97.80± 1.52 99.20± 1.20 99.69± 1.10 99.95± 1.19 
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Graph 3: Comparative Release Profile of Tolfenamic Acid in Formulation of FDCs 
 
Graph 4: Comparative Release Profile of Paracetamol in Formulations of FDCs 
The drug content of Tolfenamic Acid for all formulation 
A-1 to A-4 was well within the limits. There was no 
significant variation observed in the assay of Tolfenamic 
acid in all formulations. The drug content of Paracetamol 
was found lower side as compare to content of Tolfenamic 
acid but the loss was not significant to make any major 
impact on formulation. There was no significant variation 
observed due to co-micronization and solid dispersion for 
improvement of solubility on finished formulation of 
dispersible tablets.  
The rate of drug release was also evaluated to check the 
impact of combination of two active in FDCs. The release 
profile Tolfenamic acid in first 5 minutes time interval was 
found 70, 76, 68, and 78 % for formulation A-1, A-2, A-3, 
and A-4 respectively. The release profile of Tolfenamic 
Acid after 15 minutes for formulation A-1, A-2, A-3, A-4 
were 87, 90, 89, and 92 % respectively. The release profile 
of Tolfenamic acid after 30 minutes for formulation A-1, 
A-2, A-3, and A-4 were 95, 97, 94, and 98 respectively. 
There were significant differences observed in release 
profile of Tolfenamic acid at initial phase but it was found 
similar at later stage. Among all formulation A-2 and A-4 
showed more than 90% release of active within first 15 
minutes of dissolution as compare to remaining 
formulation A-1 and A-3. The release profile of 
Tolfenamic acid was influenced by using disintegrants. 
The use of Crospovidone showing better release as 
compare to ac di sol in existing system. 
The release profile Paracetamol in first 5 minutes time 
interval was found 28, 30, 29, and 32 % for formulation A-
1, A-2, A-3, and A-4 respectively. The release profile of 
Paracetamol after 15 minutes for formulation A-1, A-2, A-
3, A-4 were 87, 82, 85, and 80 % respectively. The release 
profile of Paracetamol after 30 minutes for formulation A-
1, A-2, A-3, and A-4 were 90, 88, 93, and 90 respectively. 
The release profile of Paracetamol remains same in all 
formulation, which showing minor impact of disintegrants 
during lubrication stage. The solubility of paracetamol 
already has enhanced by solid dispersion may be one of 
the reason behind no change in release profile of 
paracetamol by using disintegrants.  
10.0 ORGANOLEPTIC EVALUATION  
The organoleptic evaluation (Sensory Taste) such as taste 
of tablets was evaluated for all four formulation trials. The 
results of Tablet Sensory Test on taste were summarized in 
table 8.0. On the basis of evaluation the range of mean 
value was found between 4.0 and 5. There were no 
bitterness in formulation observed in combination of 
Tolfenamic acid and Paracetamol The taste of formulations 
containing strawberry flavor shown pleasant effect as 
compare to formulation containing vanilla flavor. There 
was no effect of disintegrants on the taste of formulations, 
but formulation containing Crospovidone shown rapid 
wetting tendency in saliva as compare to formulation 
containing ac di sol as disintegrants.  
 
Table 8: Organoleptic Evaluation of FDCs of Tolfenamic Acid and Paracetamol dispersible tablets 
Organoleptic Evaluation A-1 A-2 A-3 A-4 
Median Value 4.50 5.0 4.75 4.00 
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11.0 STABILITY STUDIES 
Optimized formulation (A-2) on the basis of physical, 
analytical and organoleptic evaluation was kept in stability 
at accelerated (40±20C & 75±5% RH) and intermediate 
storage condition (30 ±20C & 65±5% RH). Various 
physical and analytical parameters were evaluated as per 
the given stability protocol and summarized in table 9.0. 
There were no significant changes observed in drug 
content of Tolfenamic Acid and paracetamol on both 
storage conditions. The hardness and dispersion of tablets 
increased during accelerated storage condition but well 
within specification. There were no significant changes 
observed on physical parameters of tablets at intermediate 
storage condition. The higher humidity condition may be 
one of the reasons behind moderate changes in dispersion 
time. Moisture absorbing tendency of dispersible tablets 
also one of the reasons behind retarded dispersion of 
tablets. So tablets to be kept at closed and moisture 
protective containers to avoid any effect of moisture 
during long term storage. The implementation of alu -alu 
blister packing also eliminates the permeation of moisture 
during storage of dispersible tablets.  
 
Table 9: Stability Compilation for FDCs of Tolfenamic Acid and Paracetamol 
 
CONCLUSION 
On the basis of various physical and analytical evaluations 
formulation of FDCs of Tolfenamic Acid and Paracetamol 
can be successfully implemented in dispersible dosage 
form. There was no interaction between two active such as 
Tolfenamic acid and Paracetamol in fixed dose 
formulation. The disintegration and dispersion properties 
of finished formulation also fulfill the regulatory 
requirement (European Pharmacopoeia) in the given 
formulation.  
The usage of Crospovidone shows promising effect on 
disintegration and dispersion of formulation. The fineness 
of dispersion also comply the specification. The usage of 
disintegrants improves the release profile of co-micronized 
Tolfenamic acid but do not have any impact on solid 
dispersion of paracetamol in FDCs.  The rapid release of 
formulation which was the basic requirement of dispersible 
tablets also achieved without any changes in fixed dose 
combination of Tolfenamic acid and paracetamol.  
The positive taste results during organoleptic evaluation of 
FDCs also showing promising acceptance of FDCs in 
pediatrics and geriatric patient. There was no bitterness of 
active observed during organoleptic evaluation of tablets. 
The wetting properties of formulation showed pleasant 
mouth feeling in case of formulation containing 
Crospovidone.  
The stability profile of formulation at accelerated 
conditions such as 400C temperature and 75% relative 
humidity for 3 months does not have significant effect on 
physical and analytical properties of finished product. So 
the product found stable on specified storage and 
packaging. 
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Test Parameters Acceptance criteria 
Initial 
results 
Condition - 40°C & 75% RH 
1M 2M 3M 
Appearance White to off white colored round 
flat faced tablets 
Complies Complies Complies Complies 
Average weight (in mg) 480.00± 5.00% 480.05 481.20 480.56 479.63 
Hardness  (in N) Not less than 20 N 35 30 35 32 
Disintegration Time 
(Sec) 
Not more than 3 minutes 
60 65 62 70 
Fineness of Dispersion  To comply as per BP Complies Complies Complies Complies 
 Assay  
Tolfenamic Acid 
Paracetamol 
 
 90-110% of the labeled amount 
 
100.69 
99.20 
 
98.20 
98.36 
 
99.63 
98.10 
 
97.20 
96.25 
 Condition - 30°C & 65% RH 
Appearance White to off white colored round 
flat faced tablets 
Complies -- 
 
-- 
 
Complies 
Average weight 480.00± 5.00% 480.05 -- -- 482.10 
Hardness Not less than 20 N 35 -- -- 38 
Disintegration Time Not more than 3 minutes 60 -- -- 65 
Fineness of Dispersion  To comply as per BP Complies -- -- Complies 
 Assay  
Tolfenamic Acid 
Paracetamol 
 
 90-110%  
 90-110% of the labeled amount 
 
100.69 
99.20 
 
-- 
 
-- 
 
99.60 
99.63 
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